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Background: The inclusion of randomized controlled trials (RCTs) reported in conference abstracts in systematic reviews
is controversial, partly because study design information and risk of bias is often not fully reported in the abstract. The
Association for Research in Vision and Ophthalmology (ARVO) requires trial registration of abstracts submitted for their
annual conference as of 2007. Our goal was to assess the feasibility of obtaining study design information critical to
systematic reviews, but not typically included in conference abstracts, from the trial registration record.
Methods: We reviewed all conference abstracts presented at the ARVO meetings from 2007 through 2009, and
identified 496 RCTs; 154 had a single matching registration record in ClinicalTrials.gov. Two individuals independently
extracted information from the abstract and the ClinicalTrials.gov record, including study design, sample size, inclusion
criteria, masking, interventions, outcomes, funder, and investigator name and contact information. Discrepancies were
resolved by consensus. We assessed the frequencies of reporting variables appearing in the abstract and the trial register
and assessed agreement of information reported in both sources.
Results: We found a substantial amount of study design information in the ClinicalTrials.gov record that was unavailable
in the corresponding conference abstract, including eligibility criteria associated with gender (83%;
128/154); masking or blinding of study participants (53%, 82/154), persons administering treatment (30%, 46/154), and
persons measuring the outcomes (40%, 61/154)); and number of study centers (58%; 90/154). Only 34%
(52/154) of abstracts explicitly described a primary outcome, but a primary outcome was included in the “Primary
Outcome” field in the ClinicalTrials.gov record for 82% (126/154) of studies. One or more study interventions were
reported in each abstract, but agreed exactly with those reported in ClinicalTrials.gov only slightly more than half the
time (88/154, 56%). We found no contact information for study investigators in the abstract, but this information was
available in less than one quarter of ClinicalTrial.gov records (17%; 26/154).
Conclusion: RCT design information not reported in conference abstracts is often available in the corresponding
ClinicalTrials.gov registration record. Sometimes there is conflicting information reported in the two sources and further
contact with the trial investigators may still be required.Background
Identification of relevant randomized controlled trials
(RCTs) is an integral part in the conduct of systematic re-
views of intervention efficacy and effectiveness. RCTs are
usually identified through searching electronic databases
(e.g., PubMed, EMBASE) and handsearching (manually
screening biomedical journals, conference proceedings* Correspondence: rscherer@jhsph.edu
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reproduction in any medium, provided the orand other publications). Recently, the Institute of Medi-
cine (IOM) published guidelines stating that results from
conference abstracts should be included in systematic re-
views because conference abstracts provide an important
source of unpublished trials [1]. This is because only
about 60% of controlled clinical trials presented as con-
ference abstracts are subsequently published as journal
articles, and trials with negative or null results are pub-
lished less frequently than those with positive findings
[2]. The end result is that inclusion of the grey literature
in systematic reviews and meta-analyses leads to smallerLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for systematic reviewers, however, as reporting of study
design in abstracts is poor [4] and results reported are
often preliminary. Furthermore, there are concerns that
abstracts rarely undergo peer review. Although adoption
of CONSORT reporting guidelines for conference ab-
stracts may lead to some improvement over time, contro-
versy remains about whether to include conference
abstracts in systematic reviews [5-7].
One approach to learning more about critical design
elements of trials reported only in conference abstracts
is to seek information from other sources. For example,
a trials register such as ClinicalTrials.gov includes key
protocol items relevant to determining eligibility and
performing critical appraisal of a study.
We hypothesized that information included in a trials
register record could be used to supplement the sparse
information on study design presented in a conference
abstract. To test the hypothesis, we obtained reports of
RCTs presented at the annual meeting of the Association
for Research in Vision and Ophthalmology (ARVO) from
2007 to 2009; this is an international meeting of more
than 10,000 attendees. The ARVO organizers require that
any abstract submitted for presentation at the annual
meeting that describes a concurrently controlled trial
must be registered in an electronically searchable, pub-
licly available trials register [8]. The online conference
abstract submission form includes a box in which ab-
stract authors reporting controlled clinical trials are
asked to supply the name of the trials register and the
trial registration number where the trial was registered.
Accompanying instructions include a definition of a clin-
ical trial and a hyperlink to a frequently asked questions
page that describes trials registers, including a drop-down
menu of acceptable registers. A previous study showed
that when authors complied with this requirement, about
90% reported registering trials at ClinicalTrials.gov [9].Methods
Identification of included randomized controlled clinical
trials
We reviewed all abstracts presented at the ARVO meet-
ings from 2007 through 2009 (submitted through De-
cember 2008). Abstracts were classified as RCTs using
the definition provided in the Cochrane Collaboration’s
Handsearching Training Manual: “a study in which indi-
viduals (or other units) followed in the trial were defin-
itely assigned prospectively to one of two (or more)
alternative forms of health care using random allocation”
[10]. One person hand searched the ARVO annual meet-
ing abstracts online at http://www.arvo.org. A second
person reviewed all studies classified as an RCT by the
handsearcher and another person reviewed a sample ofabstracts not classified as an RCT [9]. Discrepancies
were resolved by consensus.
Two individuals independently extracted information
about trial registration as reported for each abstract, in-
cluding the name of the organization listed in the trial
registration box and information in the box designated
for the registration identification number. Abstracts list-
ing more than one registration number or not listing
any number were excluded from further analysis. Be-
cause 88% (276/312) of RCTs reporting a trials register
listed ClinicalTrials.gov as the trials register [9], we
chose to include only ClinicalTrials.gov records in our
study. We entered the trial register number provided in
the search box at http://www.clinicaltrials.gov and classi-
fied numbers as valid if a matching trial was identified in
ClinicalTrials.gov, and invalid if the search yielded no re-
sults. We did not attempt to identify a ClinicalTrials.gov
registration record for trials whose investigators had not
included a registration number. We retrieved all
ClinicalTrials.gov records for trials as posted (i.e., in-
cluding amendments incorporated in the record at the
time of retrieval) from May and June, 2009.
Two persons independently reviewed the abstract-
ClinicalTrials.gov pairs for inclusion. We excluded
abstract-ClinicalTrials.gov pairs that described secondary
analyses of trial data (e.g., analyses of ancillary study
data), nested case–control studies from RCT data, and
methodological studies associated with the RCT, because
the objective of our study was to compare descriptions
of the original RCT design; we also excluded pairs where
the ClinicalTrials.gov record stated that assignment to
treatment was not randomized.
Abstraction of study design characteristics
We extracted information from both the abstract and the
ClinicalTrials.gov record, including type of randomized
comparison (parallel, cross over, cluster), multi-center
status (yes/no), number randomized, and inclusion cri-
teria related to demographic characteristics of the study
population (i.e., adults, children, included sexes, presence
of a disease or condition, and/or healthy volunteers).
Masking was characterized separately as yes/no for study
participants, treatment administrators, and outcome as-
sessors. The study intervention, primary outcome, second-
ary outcomes, and study funder(s) were extracted
verbatim from the abstract and the ClinicalTrials.gov rec-
ord. We classified an outcome as the “primary” outcome
in the abstract only if it was explicitly stated as such, and
in the ClinicalTrials.gov record only if it was included in
the “Primary Outcome” field in the tabular view of the
record. We classified all other outcomes reported as “non-
primary” outcomes. The study funder was abstracted from
the “Support” field of the abstract and either the “Sponsor”
or “Collaborator” field in the ClinicalTrials.gov record.
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study funder was unclear, we classified it as non-industry
as a conservative measure. We also collected information
about study status as reported in ClinicalTrials.gov (“not
yet recruiting”, “recruiting”, “active”, or “not recruiting,
completed”). If more than one abstract had the same
registration number, we extracted information from all
relevant abstracts and reported it on a single data abstrac-
tion form. We also extracted the presence of a contact
name, telephone number, and e-mail address from the
ClinicalTrials.gov record. All data were abstracted inde-
pendently by two abstractors (RWS, LH, KD, AE, JT) on
pre-tested paper data collection forms; we extracted all in-
formation from the abstract before we extracted informa-
tion from the ClinicalTrials.gov record. Discrepancies
were resolved by consensus. All data from the paper forms
were entered into an Access database.
Data analyses
We assessed frequencies of reporting variables in the ab-
stract and the trials register. We assessed the concord-
ance between study design characteristics that were
described in both the conference abstract and the trials
register record by comparing reports of variables across
abstract-ClinicalTrials.gov pairs. We determined whether
a design characteristic that was not described in the ab-
stract was present in the trials register. We also com-
pared information reported in both sources and
characterized the level of agreement as full, partial, or
no agreement. If the abstract and the ClinicalTrials.gov
record agreed exactly or nearly exactly, we classified thisFigure 1 Flow chart of conference abstract-ClinicalTrial.gov register p
characteristics. RCT = randomized controlled trial; CT.gov = ClinicalTrials.goas full agreement. A more precise definition of an out-
come in the abstract (or register) was classified as partial
agreement while a completely different outcome in the
abstract was classified as a new outcome. We further
categorized partial agreement by type of disagreement
and source of additional information (i.e., the abstract or
the ClinicalTrials.gov record). We used SAS Version 9.2
(SAS Institute, Carey, NC) to perform all analyses.
Results
Registration of clinical trials
The handsearching results have previously been reported
[9]. Only 2.8% (496/17,953) of all abstracts presented at
ARVO from 2007 to 2009 described results of an RCT;
276 of these reported registration in ClinicalTrials.gov.
Excluding abstracts not meeting our eligibility criteria
resulted in 158 abstracts. We also excluded 4 abstracts
in which the ClinicalTrials.gov record classified the study
as not randomized. We linked each of the remaining ab-
stracts with a single ClinicalTrials.gov registration num-
ber, resulting in 154 abstract-ClinicalTrials.gov pairs for
analysis (see Figure 1).
General study design
We observed generally good agreement on the random-
ized intervention comparison described in the abstract
with what was reported in ClinicalTrials.gov (80.5%,
124/154) (see Table 1). Whether a trial was single or
multi-center was the same in 39 pairs, different in 13,
and not reported in either source for 12 pairs. For the
remaining 90 pairs, no information on multi-centerairs used for comparison of randomized controlled trial
v.
Table 1 Agreement between conference abstract and ClinicalTrials.gov register on design of randomized comparison
(n = 154 abstract-ClinicalTrials.gov pairs)
Abstract
ClinicalTrials.gov
Parallel Cross-over Cluster Within person* Factorial Other Total number of pairs
Parallel 97 5 0 1 2 7 112
Cross-over 1 20 0 0 1 0 22
Cluster 0 0 1 0 0 0 1
Within person* 8 1 0 6 0 1 16
Factorial 0 0 0 0 0 0 0
Other 2 1 0 0 0 0 3
Total number of pairs 108 27 1 7 3 8 154
* Trials in which the unit of randomization is not the individual, but an organ or part of the body (e.g., eyes).
Figure 2 Agreement between abstract and ClinicalTrials.gov
register on eligibility criteria. Bars show percent of abstract-
ClinicalTrials.gov pairs that agree (black) or disagree (gray) on eligibility
criterion, or where information on a criterion was provided in the
ClinicalTrials.gov record but not the abstract (white). Eligibility criteria
assessed are inclusion of adults, children, healthy volunteers, presence of a
condition, men and/or boys, and women and/or girls and were
categorized as present or not present. CT.gov = ClinicalTrials.gov.
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ClinicalTrials.gov.
Inclusion criteria
There was agreement between the abstract and
ClinicalTrials.gov record on inclusion criteria related to
age, the presence of a disease or condition, and whether
the trial participants were healthy volunteers (see Figure 2).
The inclusion criterion of sex was rarely reported in the
abstract, but when it was reported, the information usually
agreed with what was reported in ClinicalTrials.gov. In
contrast, the inclusion of men and/or women was always
included in the ClinicalTrials.gov record.
Intervention
At least one experimental and one control intervention
was reported in both the abstract and the ClinicalTrials.
gov record. We observed good agreement in the inter-
vention reported in the abstract with that reported in
ClinicalTrials.gov when looking at the broad categories
of treatment, prevention, diagnostic tests, and other
(Table 1). However, there was less agreement when we
compared more precise descriptions of the interventions.
The interventions described in the abstract and the
ClinicalTrials.gov record agreed exactly for 56% (88/154)
of pairs, while 37% (57/154) of pairs agreed partly and
6% (9/154) of pairs did not agree (see Table 2 for exam-
ples of disagreements). In eight pairs, partial agreement
involved small differences in the description of the inter-
vention (e.g., 100 μl versus 110 μl of a drug), and in 49
pairs, partial agreement involved additional information
about the intervention (e.g., dosage, time of administra-
tion, duration, etc.) in one source that was unavailable in
the other. In 12 pairs, additional information was present
only in the ClinicalTrials.gov record, and in 29 pairs add-
itional information was present only in the abstract. For
eight pairs, additional complementary information was
present in both sources. Partial agreement also involved
additional treatment arms: authors reported between one
and four additional treatment arms in 11 ClinicalTrials.gov records and between one and six additional treatment
arms in 25 abstracts.
Masking or blinding
We extracted information on masking separately for
study participants, treatment administrators, and out-
come assessors, finding that the ClinicalTrials.gov record
frequently provided information on masking that was
not available in the abstract (Figure 3).
Sample size
The number of study participants or sample size was
reported in both the abstract and ClinicalTrials.gov for
the majority (136/154, 88%) of studies. There were eight
studies in which a sample size was reported in the trials
Table 2 All interventions reported in ClinicalTrials.gov register and abstract that were classified as disagreements
Abstract ClinicalTrials.gov
1 1. lutein, zeaxanthin and long chain polyunsaturated fatty
acids (LCPUFAs)
1. lutein, zeaxanthin, and 3 omega polyunsaturated fatty acid (PUFA)
2. lutein and zeaxanthin 2. placebo for 3 omega (PUFA)
3. LCPUFAs, docosahexanoic acid, and eicosapentanoic
acid
3. placebo for lutein, zeaxanthin and 3 omega PUFA
4. 4 mg triamcinolone
5. 1 mg triamcinolone
6. standard of care
2 1. 0.5D lens, head fixed 1. spectacle lenses
2. 0.5D lens, head free 2. different spectacle lenses
3. 1.0D lens, head fixed
4. 1.0D lens, head free
5. plano lens, head fixed
6. plano lens, head free
3 1. folic acid, vitamin B6 and vitamin B12 1. aspirin ± vitamin E
2. placebo 2. vitamin E ± vitamin C
3. vitamin E ± vitamin C ± beta carotene ± folate
4. placebo
4 1. photocoagulation using ETDRS grid 1. 810 nm diode laser photocoagulation
2. photocoagulation with normal micro-pulsed technique 2. argon laser photocoagulation
3. photocoagulation with high density micro-pulsed
technique
5 1. 0.3 mg ranibizumab monthly for 6 months 1. treatment with ranibizumab until resolution of macular edema or as macular
edema occurs
2. 0.5 mg ranibizumab monthly for 6 months 2. treatment with ranibizumab until resolution of edema and pigment epithelial
detachment or as macular edema or pigment epithelial detachment occur
3. 3 doses of ranibizumab, then treatment until macular
fluid or pigment epithelial detachment absent
6 1. laser photocoagulation 1. early treatment
2. conventional treatment 2. standard of care
7 1. SofFlex IOL 1. Acrysof Natural lens
2. SofPort IOL 2. AmoSensar Lens
8 1. plano lens plus weekend atropine 1. patching plus near activities at least one hour per day
2. weekend atropine 2. atropine plus near activities at least one hour per day
3. full spectacle correction plus weekend atropine
4. 2 hours daily patching
9 1. contact lens care system with polyquaternium-1 and
MAPD
1. silicone hydrogel contact lens
2. contact lens care system with PHMB 2. 1XPMBH preserved MPS
3. 1XPolyguad/Aldox MPS
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sample sizes for pairs where the abstract author stated
that the number of participants represented all random-
ized study participants and the status on the
ClinicalTrials.gov record was either “completed” or “ac-
tive, not recruiting” (see Table 3), and found good
agreement.Outcomes
Authors reported 800 outcomes in 152 abstracts; no out-
comes were reported in 2 abstracts. Thirty four percent
(52/154) of abstracts and 82% (126/154) of ClinicalTrials.
gov records explicitly described a primary outcome
(Table 4). Of the 80 primary outcomes reported among
the 40 abstract - ClinicalTrials.gov pairs, 14 (18%) were
Figure 3 Agreement between abstract and ClinicalTrials.gov
register on masking by study role. Bars show percent of abstract-
ClinicalTrials.gov pairs that did not provide information on masking
or blinding (black), agree (dark gray), or disagree (light gray), or
where information was provided in the ClinicalTrials.gov record but
not the conference abstract (white) on masking of study
participants, persons administering the treatment, or persons
measuring outcomes. Masking was categorized as present or not
present. CT.gov = ClinicalTrials.gov.
Table 4 Agreement between conference abstract and
ClinicalTrials.gov register on reporting of one or more














primary outcome 40 12 52
Not reporting a
primary outcome 86 16 102
Total number of
pairs 126 28 154
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as partial agreement (see Table 5). Partial agreement typ-
ically involved a more explicit description of an outcome
as shown in in Table 6. Of the remaining 27 primary out-
comes reported in the abstract, 13 were reported else-
where in the ClinicalTrials.gov record. There was poor
agreement between non-primary outcomes reported in
the abstract with those reported in ClinicalTrials.gov (see
Table 5).
Funders
One hundred forty-six unique funders were identified in
either the abstract or the ClinicalTrials.gov record. AtTable 3 Comparison of number of randomized study
participants reported in abstract with number reported
in ClinicalTrials.gov
Sample size comparisons for 66 abstract-ClinicalTrials.gov pairs
No. (%) pairs with exact match 20 (39)
No (%) pairs with percent difference* ± 10% 18 (27)
No (%) pairs with percent difference* > 10% 28 (42)
Range of percent differences −106.6 to 88.7
Average (SD) percent difference 1.0 (32.9)
*Percent difference = ((No. participants reported in abstract – No. reported in
ClinicalTrials.gov)/ No. participants reported in ClinicalTrials.gov) X 100.
Includes abstract-ClinicalTrials.gov pairs where number of participants in
abstract included all randomized study participants and the status on the
ClinicalTrials.gov record was either “completed” or “active, not recruiting.least one funder was reported in each ClinicalTrials.gov
record, but only in 62% of abstracts (95/154). More than
one funder was reported in 41 ClinicalTrials.gov records
and in 19 abstracts. The same funder(s) were reported in
both sources for 10 studies. We observed partial agree-
ment across funders for 37 pairs, in which an additional
or different funder was reported in either the abstract or
in the ClinicalTrials.gov record.Contact information
The name of a contact person was included on 83%
(128/154) of ClinicalTrials.gov records, but a phone
number was found on only 25, and an email address on
26 records. No contact information was provided on any
conference abstract except author name and affiliation.Discussion
A substantial amount of additional information on study
design was available on the ClinicalTrials.gov record that
was not presented in a corresponding conference abstract.
Information on multi-center status, eligibility criteria with
respect to sex, who is masked, and primary outcome isTable 5 Agreement between conference abstract and
ClinicalTrials.gov register on outcomes (n = 40 abstract-
ClinicalTrials.gov pairs reporting ≥ 1 primary outcome






No. (%) No. (%)
Total outcomes reported in
abstract 80 (100) 708 (100)
Complete agreement 14 (18) 57 (8)
Partial agreement 39 (49) 205 (29)
Not reported in ClinicalTrials.
gov 27 (34) 446 (63)
Table 6 Examples of primary outcomes reported in ClinicalTrials.gov register with primary outcome reported in
abstract classified as “partial agreement”
Abstract ClinicalTrials.gov Classified as
1 Retinal thickness in the peak oedematous field on the retinal
maps of the fast module scans of the Stratus OCT
Retinal thickness by fast retinal thickness mapping by optical
coherence tomography at 0,2,4,8,10,15,20,30,60,90,120,and
180 min after last swallow of glycerol
Extra information in
ClinicalTrials.gov
2 Visual acuity Mean change in best corrected visual acuity as assessed by
number letters read correctly on ETDRS eye chart at starting
test distance of 4 meters from baseline to 1,3,6 months
Extra information in
ClinicalTrials.gov
3 ETDRS best corrected visual acuity at 2, 6 and 12 weeks; OCT
at 2 and 6 weeks; fluorescein angiography at 2 and 6 weeks




4 Change from baseline in major symptom complex score
over period 1, consisting of runny nose, sniffles, itchy nose,
nose blows, sneezes, and watery eyes




5 Retinal detachment rate; surgery-related complications;
patient comfort; refractive change; visual acuity; OCT
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record. In addition, the name of a contact was included in
83% of ClinicalTrials.gov records, so that if desired infor-
mation about the trial was not available, or conflicted with
what was reported in the abstract, a systematic reviewer
could contact the study author directly, although contact
information was provided in a minority of ClinicalTrials.
gov records.
Thus, if a trial registration number is available for a
study to be included in a systematic review, a systematic
reviewer may be able to find additional information
about study design in a trials register record. However,
there are caveats to these findings. First, information
about trial registration may not be required nor provided
by conference organizers generally. Second, we encoun-
tered numerous disagreements between the information
provided in the conference abstract with information
contained within the ClinicalTrials.gov record on a num-
ber of items. ClinicalTrials.gov was originally intended to
provide a source of information about the existence of a
trial for patients and clinicians, to diminish redundant re-
search effort, and to alert researchers to the possibility of
publication bias. Currently it provides limited proto-
col information, although it would be a natural re-
pository for full protocols. A published protocol or
design and methods paper would provide more infor-
mation, but until public availability of all trial proto-
cols is achieved, trials registers serve as surrogates
for study protocols.
The findings from our study relate specifically to
ARVO abstracts and ClinicalTrials.gov and may not be
applicable to other conference abstracts or trials regis-
ters. Furthermore, our requirement that a valid
ClinicalTrials.gov registration number be reported on
the abstract submission form could mean that studieswere actually registered but the number not recorded or
incorrectly recorded.
Previous studies have identified discrepancies between
trials register records and associated full length publica-
tion on study design characteristics, especially related to
the description of primary and secondary outcomes
[11-16]. In our study, we found discrepancies related to
the detailed descriptions of study interventions and out-
comes reported in the conference abstract compared
with those reported in the ClinicalTrials.gov record. Fre-
quently there was more information available in the ab-
stract than was in the ClinicalTrials.gov record (e.g.,
dose or duration of treatment). Most disturbing was the
appearance of additional treatment arms in the abstract
that were not included in the register, suggesting that in-
vestigators are not regularly updating the trial register
record as required or that abstracts represent prelimin-
ary findings, before an arm was dropped.
The discrepancies in outcomes may be an indication
of error, selective outcome reporting, or simply due to
investigators not updating the ClinicalTrials.gov record
in a timely manner. We obtained register records that
were available shortly following presentation of abstract
results at ARVO, so any additional outcomes or changes
in the study design should have been incorporated into
the trial register as an amendment to the protocol items.
In addition, we compared outcomes in only one direc-
tion, i.e. from abstract to Clinicaltrials.gov record. We
did not do the reverse analysis (i.e. comparing all out-
comes reported in ClinicalTrials.gov with those reported
in the abstract) because we would not expect an abstract
to include all outcomes reported in ClinicalTrials.gov. In
so doing, we did find that sometimes the outcome
reported in the abstract as the “primary” outcomes was a
secondary outcome in the ClinicalTrials.gov record.
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comes reported as results with the specified out-
comes in the ClinicalTrials.gov record. Results
reporting in ClinicalTrials.gov opened in September
2008. When we retrieved the records in May and
June 2009, none of the records included any study
results when downloaded.
Other studies have also found discrepancies between
the description of an RCT as reported in an abstract
with what was reported in a full length publication
[17-21]. It would be of interest to make a three-way
comparison of a conference abstract, trial register and
results record, and full length publication to determine
congruence between these sources of information. It
would also be useful for authors to include conference
abstracts in the ClinicalTrials.gov record as a publica-
tion, in addition to full length publications.
Whether the study results reported in an abstract
should be included in a systematic review or used to
make clinical decisions is unclear. That results from ab-
stracts are being included in systematic reviews has been
reported in a sample of meta-analyses indexed in
Medline [7], for health technology assessments [5], and
for drug formulary decision-making [22]. Including ab-
stracts in systematic reviews is recommended by IOM
[1], the Cochrane Collaboration [23], and the Agency for
Health Care Research and Quality [24], although caution
is urged due to the preliminary nature of abstract results
[25,26]. Results from a Cochrane systematic review
found that there was an overall smaller treatment effect
if systematic reviewers included abstract results in the
review compared to the treatment effect size without ab-
stracts included, although this finding was not statisti-
cally significant [3]. Additional investigators report
similar results, showing small reductions in the size of
the treatment effect when abstract results are included
in a systematic review [27,28].
Overall, given our findings, we would encourage sys-
tematic reviewers to take advantage of the information
provided in the ClinicalTrials.gov record to supplement
the information provided in an abstract. We did not rec-
ord the amount of time it took to extract information
for each record. Because the trials register number was
available, matching the abstract to the registry report
was straightforward. Extracting all the information we
did for our study was somewhat time consuming, and
we found that it was more efficient to obtain the infor-
mation from the tabular view in ClinicalTrials.gov rather
than the full text view. Most likely, it would take much
less time for a systematic reviewer looking for specific
information. We would caution systematic reviewers to
exercise care in using data from a trials register record,
however, as with any unpublished study result. In many
cases, systematic reviewers may not be able todistinguish between conflicting reports and still find it
necessary to contact the study investigators. For this
situation, the ClinicalTrials.gov record frequently pro-
vides contact information that is almost always missing
from a conference abstract.
Conclusions
Systematic reviewers may find additional information
about an RCT in the ClinicalTrials.gov record to supple-
ment the information provided in a conference abstract.
However, it may still be necessary to contact study in-
vestigators for information not included in either the ab-
stract or ClinicalTrials.gov record, or that is in conflict
between the two sources.
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